VACCINEX, INC.
VCNXOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $601,000 | $570,000 | $275,000 | $900,000 | $625,000 | $523,000 |
| Operating income | −$18.7M | −$22.9M | −$19.9M | −$22.5M | −$28.3M | −$32.0M |
| Net income | −$18.6M | −$20.3M | −$19.8M | −$22.4M | −$28.9M | −$31.9M |
| Total assets | $2.6M | $3.6M | $8.0M | $9.8M | $11.7M | $4.6M |
| Total liabilities | $5.1M | $5.9M | $2.8M | $2.4M | $14.3M | $6.9M |
| Equity | −$2.5M | −$2.3M | $5.2M | $7.4M | −$26.6M | −$26.2M |
| EPS (diluted) | $-8.88 | $-43.68 | $-98.05 | $-0.78 | — | — |
| Shares out. | 1.2M | 49.9M | 42.7M | 28.4M | 16.4M | 11.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −3117.3%
- Net margin
- −3100.5%
- Return on equity
- 749.0%
- Return on assets
- −717.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 195.8%
- Debt / equity
- —
- Book value / share
- $-2.02
- Revenue growth (YoY)
- 5.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -505.74distress
- Accruals / assets
- −94.3%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Friedberg AlbertDirector | Nov 14, 2024 | Grant | 30,756 | $3.25 |
| Zauderer MauriceOfficer — President and CEO | Nov 14, 2024 | Grant | 46,153 | $3.25 |
| Zauderer MauriceOfficer — President and CEO | Sep 18, 2024 | Option exercise | 38,610 | $5.64 |
| Friedberg AlbertDirector | Sep 18, 2024 | Option exercise | 214,286 | $5.64 |
| Friedberg AlbertDirector | Aug 9, 2024 | Buy | 100 | $4.51 |
| Friedberg AlbertDirector | Aug 5, 2024 | Buy | 3,653 | $4.60 |
| Friedberg AlbertDirector | Aug 1, 2024 | Buy | 11,703 | $4.72 |
| Friedberg AlbertDirector | Jul 31, 2024 | Buy | 100,629 | $5.74 |
| Friedberg AlbertDirector | May 29, 2024 | Buy | 957 | $4.95 |
| Van Strydonck, Gerald E.Director | May 10, 2024 | Grant | 543 | $5.75 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3,615 | 4.5 | -9.5% |
| Apr 30, 2026 | 3,994 | 1.0 | +167.9% |
| Apr 15, 2026 | 1,491 | 1.0 | +6.9% |
| Mar 31, 2026 | 1,395 | 1.0 | -40.7% |
| Mar 13, 2026 | 2,351 | 1.0 | +58.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMar 19, 2025
- Delisting / listing-standard notice · Regulation FD disclosureMar 7, 2025
- Delisting / listing-standard notice · Other material eventDec 17, 2024
- Entered a material agreement · Unregistered equity saleNov 14, 2024
- Delisting / listing-standard noticeOct 9, 2024
- Entered a material agreement · Unregistered equity saleSep 19, 2024
- Director / officer changeSep 13, 2024
- Other material eventAug 20, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.